← Leaderboards
Jeffrey Daniel Cooney
University Of Texas Hlth Science Center
$152,985
Attributed
$152,985
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $40.5K · FY2016–20$50K$37.5K$25K$12.5K$0
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$152,985 · 1
By mechanism
F30$152,985 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Science Center
Same institution · by research overlap
- Ricardo C Aguiar$4,897,608
- Gregg Joshua Silverman$11,844,811
- Juli Bai$1,402,984
- Laurence Morel$26,519,374
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesGeneticFrap1 GeneAlleles1-Phosphatidylinositol 3-KinaseB-Cell LymphomasAblationAgreementB-LymphocytesB Lymphoid MalignancyCancer Clinical TrialCancer PatientCareerCell LineCombinatorialB-Cell NeoplasmCritical PathwaysCyclic AmpDesignEnsureEnzymesEventFda ApprovedGrowth
Grant awards (5)
The cyclic AMP/phosphodiesterase4 axis regulates proximal B cell receptor signaling and offers a new therapeutic strategy for B cell lymphomas$8,430
F30 · FY2020 · CA · contact PI
The cyclic AMP/phosphodiesterase4 axis regulates proximal B cell receptor signaling and offers a new therapeutic strategy for B cell lymphomas$40,507
F30 · FY2019 · CA · contact PI
The cyclic AMP/phosphodiesterase4 axis regulates proximal B cell receptor signaling and offers a new therapeutic strategy for B cell lymphomas$40,028
F30 · FY2018 · CA · contact PI
The cyclic AMP/phosphodiesterase4 axis regulates proximal B cell receptor signaling and offers a new therapeutic strategy for B cell lymphomas$32,244
F30 · FY2017 · CA · contact PI
The cyclic AMP/phosphodiesterase4 axis regulates proximal B cell receptor signaling and offers a new therapeutic strategy for B cell lymphomas$31,776
F30 · FY2016 · CA · contact PI